title: [Bevacizumab in the first-line therapy of advanced NSCLC].
abstract: The angiogenesis inhibitor bevacizumab, a VEGF antagonist, was approved in the European Union in August 2007 for the first-line therapy of inoperable, advanced or recurrent non-small-cell lung cancer, in combination with a platin-based chemotherapy regimen. Tumors with predominantly squamous-cell histology must be excluded. Two recent phase-III studies have shown that bevacizumab, combined with carboplatin and paclitaxel (E4599) or cisplatin and gemcitabine (AVAiL), significantly prolongs overall survival and/or progression-free survival. The most common adverse events during therapy with bevacizumab are hypertension and proteinuria - both are usually well manageable. By applying correct patient selection criteria the risk of pulmonary bleeding can be greatly reduced.
authors.forename: Norbert
authors.initials: N
authors.lastname: Hasenöhrl
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
vernacular_title: Bevacizumab in der First-Line-Therapie des fortgeschrittenen NSCLC.